---
title: "CeriBell, Inc. (CBLL.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/CBLL.US.md"
symbol: "CBLL.US"
name: "CeriBell, Inc."
industry: "Health Care Equipment"
---

# CeriBell, Inc. (CBLL.US)

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Location | US Market |
| Website | [www.ceribell.com](https://www.ceribell.com) |

## Company Profile

CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and he...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-03-01T04:30:12.000Z

**Overall: C (0.45)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 62 / 186 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 36.09% |  |
| Net Profit YoY | -32.03% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 4.52 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 702.76M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 89.06M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -30.83% | E |
| Profit Margin | -59.97% | E |
| Gross Margin | 87.89% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 36.09% | A |
| Net Profit YoY | -32.03% | D |
| Total Assets YoY | -13.14% | E |
| Net Assets YoY | -18.74% | E |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -166.75% | D |
| OCF YoY | 36.09% | A |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.42 | C |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 20.67% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - CeriBell, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-30.83%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-59.97%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "87.89%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "36.09%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-32.03%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-13.14%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-18.74%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-166.75%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "36.09%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.42",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "20.67%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Inspire Medical (US.INSP) | A | B | A | A | B | A |
| 02 | Delcath (US.DCTH) | C | A | B | A | A | A |
| 03 | Abbott Laboratories (US.ABT) | B | C | C | B | C | B |
| 04 | Intuitive Surgical (US.ISRG) | A | B | C | A | B | B |
| 05 | Stryker (US.SYK) | A | B | C | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -13.16 | 149/181 | - | - | - |
| PB | 4.52 | 93/181 | 4.53 | 3.43 | 2.66 |
| PS (TTM) | 7.89 | 106/181 | 9.59 | 8.58 | 5.80 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-25T05:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 7 | 88% |
| Overweight | 1 | 13% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 18.67 |
| Highest Target | 32.00 |
| Lowest Target | 24.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/CBLL.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/CBLL.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/CBLL.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.